iBio

Health biotech genetics pharma platform robotics

iBio develops and offers product applications of its iBioLaunch and iBioModulator platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.

Revenue(FY, 2016)

$948 K

Market capitalization(2018-04-23)

$16.4 M

Type

Public

Newark, US

Founded

2008

Size (employees)

43 (est)

Website

ibioinc.com

iBio was founded in 2008 and is headquartered in Newark, US

Report incorrect company information

Key People/Management at iBio

Robert Kay

Executive Chairman and Chief Executive Officer

James Mullaney

Chief Financial Officer

Robert Erwin

President

Terence Ryan

Chief Scientific Officer

Wayne Fitzmaurice

Vice President, Intellectual Property

Report incorrect company information

iBio Office Locations

iBio has an office in Newark

Newark, US (HQ)

100 9 Innovation Way

Show all (1)

Report incorrect company information

iBio Financials and Metrics

iBio Financials

iBio's revenue was reported to be $948 k in FY, 2016 which is a 48.8% decrease from the previous period.

Summary

USD
Revenue (Q3, 2017)	37 k
EBIT (Q3, 2017)	(3.9 m)
Market capitalization (23-Apr-2018)	16.4 m
Cash (31-Mar-2017)	12.4 m

iBio's current market capitalization is $16.4 m.

Source: SEC Filings

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	205 k	1.9 m	948 k
Revenue growth, %		803%	(49%)
General and administrative expense	3.9 m	5 m	7.7 m
R&D expense	1.9 m	3.5 m	3.2 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue				819 k	349 k	160 k	134 k	379 k	135 k	75 k	37 k
General and administrative expense	949 k	1.1 m	951 k	1.1 m	1.2 m	1.4 m	1.7 m	2.4 m	2.5 m	2.4 m	2.8 m
R&D expense	552 k	585 k	343 k	1.2 m	815 k	551 k	704 k	1 m
Operating expense total	(240 k)	1.6 m	1.3 m	2.2 m	2 m	2 m	2.4 m	3.5 m	3.3 m	3.4 m	4 m

show all

Source: SEC Filings

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	3.6 m	9.5 m	23 m
Inventories	118 k	182 k	264 k
Current Assets	3.9 m	10.1 m	23.9 m
PP&E	6 k	13 k	25.6 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	3.4 m	5.7 m	4.3 m	3.5 m	8.1 m	8.4 m	6.7 m	21.9 m	20.1 m	16.3 m	12.4 m
Current Assets	4.6 m	6.9 m	5.5 m	4.1 m	9 m	9.1 m	7.2 m	22.7 m	20.5 m	16.7 m	13 m
PP&E		5 k	7 k	20 k	14 k	10 k	14 k	25.8 m	25.6 m	25.5 m	25.8 m
Total Assets	7.3 m	9.6 m	8.2 m	6.7 m	11.4 m	11.4 m	9.4 m	50.7 m	48.1 m	44.2 m	40.7 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	(3.7 m)	(6.6 m)	(10.7 m)
Depreciation and Amortization	361 k	363 k	940 k
Inventories	97 k	(64 k)	(82 k)
Accounts Payable	56 k	806 k	(125 k)

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Net Income	379 k	(1.6 m)	(1.3 m)	(1.4 m)	(1.7 m)	(1.8 m)	(4.1 m)		(3.6 m)
Depreciation and Amortization						92 k	184 k	537 k	412 k	826 k	1.3 m
Accounts Payable			1.1 m	516 k	815 k	171 k	190 k	342 k	53 k	(255 k)	7 k
Cash From Operating Activities						(1.1 m)	(2.8 m)	(5.3 m)	(2.3 m)	(5.8 m)	(9.4 m)